Spero Therapeutics (SPRO) Net Cash Flow (2016 - 2026)

Spero Therapeutics has reported Net Cash Flow for 11 years, with the latest figure at $15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 496.4% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (up 121.69% YoY), and the FY2025 full-year result was -$12.6 million, up 46.15% from the prior year.
• Net Cash Flow for Q1 2026 stood at $15.9 million, up from -$8.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $58.7 million in Q4 2022, with the low at -$40.5 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$3.3 million across 5 years, with a median of -$8.4 million in 2025.
• The largest YoY upside for Net Cash Flow was 21431.27% in 2022 against a maximum downside of 395.57% in 2022.
• Spero Therapeutics' Net Cash Flow stood at $58.7 million in 2022, then sank by 129.82% to -$17.5 million in 2023, then sank by 33.78% to -$23.4 million in 2024, then surged by 64.31% to -$8.4 million in 2025, then soared by 289.97% to $15.9 million in 2026.
• The last three Net Cash Flow figures came in at $15.9 million (Q1 2026), -$8.4 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.